Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

India Keeps Eye On SGLT2 Inhibitors Amid Safety Signals

Executive Summary

After recent safety warnings from both US FDA and Health Canada, India steps ups surveillance, but Janssen and AstraZeneca tell Pink Sheet that data indicate no major safety concerns, at least so far.

You may also be interested in...



Hips Don’t Lie: J&J Faces Compensation Maelstrom In India Over Faulty ASR Implants

Johnson & Johnson is caught in the eye of a storm in India, after an expert panel recommended compensation for patients affected by its 'faulty' ASR hip implants.  A stinging report by the panel raises several questions around J&J’s alleged “lack of seriousness” in addressing the issue - charges that the company denies - though it remains to be seen how the Indian government ensures that Indian patients get a fair deal.

Dapagliflozin Alliance Targets Surging Indian Diabetes Market

AstraZeneca has struck an agreement with India’s Sun Pharma under which the two companies will promote and distribute the UK-based firm’s diabetes drug dapagliflozin under different brand names. The deal means AstraZeneca can benefit from Sun’s wide distribution network to penetrate India’s rapidly growing diabetes sector while retaining intellectual property rights.

Forxiga debuts in India at fraction of global prices

The Indian diabetes segment continues to buzz with action. Close on the heels of going through with a second brand plan for saxagliptin, AstraZeneca Pharma has launched Forxiga (dapaglifozin), for type 2 diabetes, on the Indian market at a fraction of international prices.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS124047

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel